A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin

S.J. ALARFAJ1, M.M. BAHAA2, H.A. YASSIN3, E. EL-KHATEEB4,5, F.A. KOTKATA4, M.A. EL-GAMMAL6, A.I. ELBERRI7, E. HABBA8, E.E. ZIEN EL-DEEN9,10, M.O. KHRIEBA2, T.A. EL-MASRY11, W.A. NEGM12, E.I. ELBERRI4

1Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
2Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt
3Pharmaceutics Department, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Egypt
4Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Al-Gharbia, Egypt
5Certara UK Limited (Simcyp Division), Sheffield, UK
6Pharmacology and Biochemistry Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt
7Department of Zoology, Faculty of Science, Menoufia University, Genetic Engineering and Molecular Biology Division, Shebin El-Kom, Menoufia, Egypt
8Tropical Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt
9Pharmaceutical Technology Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt
10Pharmaceutics Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, Egypt
11Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt
12Department of Pharmacognosy, Faculty of Pharmacy, Tanta University, Tanta, Egypt

S.J. Alarfaj and M.M. Bahaa contributed equally to this work

**Abstract.** – **OBJECTIVE:** Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver metabolic disease affecting millions globally. This study aimed to assess the safety and efficacy of a high oral loading dose of cholecalciferol supplement on NAFLD patients and to investigate its potential role on serum inflammatory biomarkers.

**PATIENTS AND METHODS:** One hundred patients with NAFLD and type 2 diabetes mellitus were involved in the study. Eligible patients were randomized among two equal groups. Group 1 received the standard conventional therapy in addition to a placebo. Group 2 received the conventional therapy plus cholecalciferol for 4 months. The improvement in the patients’ glycaemic control parameters, liver function tests, lipid profile, and serum 25-hydroxy vitamin D at the end of the study was set as a primary outcome. The secondary outcome was the decrease in steatosis grade in the ultrasound and high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α), signal transducer and activator of factor-3 (STAT-3), nitric oxide (NO), malondialdehyde (MDA), and hepassocin serum levels at the end of the study.

**RESULTS:** Group 2 revealed a significant reduction in the serum levels of lipid profile measures, hs-CRP, alanine aminotransferase (ALT), STAT-3, NO, hepassocin, and MDA compared to the baseline and group 1 results. Whereas group 1 did not show these significant changes. Both groups observed no significant changes in glycemc index, TNF-α, aspartate aminotransferase (AST), and albumin levels.

**CONCLUSIONS:** Cholecalciferol is recommended as additional therapy to modulate lipid peroxidation and systemic inflammation alongside other NAFLD therapies.

**Key Words:** Non-alcoholic fatty liver, Cholecalciferol, Hepassocin, STAT-3, hs-CRP.
**Introduction**

Non-alcoholic fatty liver disease (NAFLD) is widely regarded as the leading cause of chronic liver disease and a major public health concern worldwide. The incidence of NAFLD, closely related to obesity, is believed to be 24% worldwide, causing a significant clinical and financial burden on many nations, including the United Kingdom\(^1,2\). NAFLD, a broad term embracing a variety of histopathologies from hepatic steatosis (non-alcoholic fatty liver, NAFL) through non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis, is defined physiologically by excess lipid buildup in the liver. The disease’s phenotype and its progress vary greatly between individuals and are affected by complex interactions between genetic, metabolic, and environmental factors\(^3,4\).

Due to the excessive fat accumulation in this disease, NAFLD affects more than 70% of people with metabolic syndrome (MS)\(^5\). The combination of numerous factors, including environmental, genetic, hormonal, and dietary factors, is the primary cause of NAFLD. The most frequent risk factors for NAFLD beginning are obesity and MS, which are also associated with a faster rate of disease development\(^6\).

Until now, weight loss and lifestyle change have been the mainstay of treatment for NAFLD. According to guidelines\(^7\), no approved pharmacological therapy exists, and many patients do not respond to non-pharmacological interventions alone. As a result, numerous medications for treating NAFLD with various mechanisms of action are gaining great interest and are currently undergoing clinical investigation\(^8\).

Different dietary elements may have different effects on the onset and/or progression of the disease and have been linked to the pathophysiology of NAFLD. For instance, dietary macronutrients appear to variably affect lipid building up in the liver through several molecular and cellular pathways, apart from their role in energy production\(^9,10\). Similarly, how micronutrient deficiencies have been linked to NAFLD and their therapeutic targeting has a mechanistic explanation. Unfortunately, nutritional supplements have only been the target of limited intervention trials in individuals with NAFLD, with various results\(^11\). In pre-clinical animals, vitamin D has been demonstrated to have anti-proliferative, anti-inflammatory, and anti-fibrotic characteristics that have been proven to slow the worsening of NAFLD\(^2,13\).

Moreover, pediatric NAFLD is a notable example of the prevalent poor vitamin D status and low dietary vitamin D intake\(^14,15\). However, vitamin D supplementation intervention trials in NAFLD patients have varied durations, dosages, and outcome measures. There are still concerns about the best regimens for treating chronic liver disease\(^16\). Various clinical trials\(^17-19\) have demonstrated the correlation between NAFLD and low vitamin D levels. Moreover, it correlates with the degree of fibrosis and inflammation in NAFLD.

Hepassocin (HPS) is a hepatokine involved in liver regeneration that is produced in hepatoma cells *in vitro* by the hepatocyte nuclear factor 1 (HNF1)-regulated IL-6/IL-6R/STAT3 pathway\(^20\). HPS was detected in high serum levels in mice and patients with NAFLD, and HPS levels were linked to non-alcoholic steatohepatitis\(^21\). In mice, overexpression of hepatic HPS-induced lipid building up by an extracellular signal-regulated kinase 1/2 (ERK1/2)-dependent pathway\(^22\). In HPS knock-out mice, HPS is also attributed to the development of IR and type 2 diabetes mellitus (T2DM) through ERK1/2 activation\(^23\).

The current study aimed to investigate the effect of a high oral loading dose of vitamin D on glycaemic parameters, lipid profile, and oxidative and inflammatory biomarkers.

**Patients and Methods**

This research was conducted at Tanta University’s Hepatology Department, Faculty of Medicine, from October 2022 to February 2023. The study included 100 outpatient clinic patients who met the inclusion criteria. Tanta University Faculty of Medicine’s National Research Ethics Committee approved this study with approval code (35927/10/2022). The study’s design and methods were in accordance with the Helsinki Declaration in 1964 and its later amendments. Patients were informed that they could withdraw from the study at any moment. Trial registration identifier: NCT05578404.

**Inclusion Criteria**

- Male or female adult patients (> 19 years).
- Fatty liver patients diagnosed by using upper abdominal ultrasound echography (US) and with T2DM diagnosed according to American Diabetes Association (ADA) 2019 criteria and treated with metformin\(^24\).
**Exclusion Criteria**
- Pregnant and/or lactating women.
- Excessive alcohol use (Consistent with the national definition, excessive alcohol consumption was defined as binge drinking (≥ 4 drinks per occasion for a woman and ≥ 5 drinks per occasion for a man)\textsuperscript{25}.
- Chronic liver diseases such as viral, drug-induced, and autoimmune hepatitis.
- Patients suffering from chronic kidney disease.
- Patients with thyroid disorders.
- Hypersensitivity to cholecalciferol.
- Patients taking vitamin D supplementation and medications affecting calcium/vitamin D metabolism.
- Inflammatory bowel disease patients taking systemic steroids or biological therapy.
- Patients already taking anti-inflammatory drugs or other therapies that may affect the serum levels of the measured parameters.

**Study Intervention**
This was a randomized, controlled, double-blind clinical study that investigated the safety and efficacy of cholecalciferol in the treatment of NAFLD patients and was conducted at Tanta University’s Hepatology Department. This research was registered as NCT05578404 on WWW.ClinicalTrials.gov in 2022. According to the CONSORT flow diagram in Figure 1, the patients were randomly assigned to groups 1 or 2 (n = 50) based on the days of hospitalization. The study included 150 patients who were screened. Forty patients were excluded from the study; 35 could not meet the inclusion criteria outlined above, and 15 declined to participate. One hundred patients continued and were involved in the study and randomized into one of the following two groups:
- Group 1: 50 patients received the standard conventional therapy plus a placebo for 4 months.
- Group 2: 50 patients were given the standard conventional therapy plus cholecalciferol. Cholecalciferol was given at a high oral loading dose of 300,000 IU (Devit\textsuperscript{R} 300,000 IU, Ampoule, Deva Pharma, Istanbul, Turkey), followed by a daily oral dose of 800 IU IU (Vi-drop\textsuperscript{R}, Oral Drops, Medical Union Pharmaceuticals company, Nasr City, Egypt) for 4 months. This dose was given to all 50 participants irrespective of their initial 25(OH)D levels.

Regular exercise in the form of any physical activity, such as walking, cycling, etc., for 30-45 minutes at a minimum five days a week, as well as calorie restriction in overweight and obese patients (1,200-1,500 and 1,000-1,200 kcal/day for men and women, respectively), were all components of the standard conventional therapy in both groups. To guarantee the correct treatment assignment, study drugs were administered to patients by an unblinded pharmacist; however, this pharmacist was excluded from the outcome eval-

![CONSORT flow diagram of patient allocation.](image-url)
Evaluation. Based on the abdominal US performed by a blinded radiologist, where the liver brightness and liver parenchyma with diffuse echogenicity confirm the diagnosis, all patients were determined to have NAFLD.

**Study Procedures**

Age, sex, and weight were among the details that the patients’ information was collected. Based on the results of liver brightness, deep attenuation of the US signal, hepatorenal echo contrast, and the blurring of vessels, the fatty liver was graded as none (0), mild (1), moderate (2), or severe (3). The grading was recorded two times; the first time at the beginning of the study and the second time after 4 months.

**Laboratory Measurements and Clinical Assessments**

Anthropometric measurements of each patient, including height in meters, weight in kilograms, and waist circumference (WC) in centimeters, were measured at the start and end of the trial (measured midway between the 12th rib and the iliac crest). Moreover, the body mass index (BMI) was determined (BMI = weight in kg divided by height in m²). The World Health Organization (WHO) defines overweight as having a BMI of more than 25 kg/m², and obesity as having a BMI greater than 30 kg/m². Patients were regarded to be vitamin D deficient when their 25(OH)D levels were less than 20, insufficient when they were between 21 and 29, and sufficient or normal when they were at 30 ng/ml or more.

Serum samples were collected from each patient and used to measure biochemical markers by Enzyme-Linked Immunosorbent Assay (ELISA) using widely available ELISA kits according to the manufacturer’s instructions (Sunredio, Shanghai, China) for measuring serum STAT-3 (Kit Catalogue No.: 201-12-0651), serum TNF-α (Kit Catalogue No.: 201-12-0083), MD (Kit Catalogue No.: 201-12-1372), NO (Kit Catalogue No.: 201-12-1511), hepassocin (Kit Catalogue No.: 201-12-1547), hs-CRP (Kit Catalogue No.: 201-12-1806), cholescalciferol (Kit Catalogue No.: 201-12-1547), albumin (Kit Catalogue No.: 201-12-1806), and insulin (kit Catalogue No.: 201-12-0011).

Enzymatic colorimetric techniques were also used to quantify the following laboratory tests: triglycerides (TG mg/dl), total cholesterol (TC mg/dl), low-density lipoprotein (LDL mg/dl), and high-density lipoprotein (HDL mg/dl), alanine and aspartate transaminases (ALT and AST, respectively), fasting blood glucose (FBG mg/dl).

Insulin resistance was calculated by the homoeostasis model assessment insulin resistance (HOMA-IR) method using the product of fasting insulin and FBG divided by 405.

All patients were followed up weekly by the clinical pharmacist in charge through patient encounters to ensure compliance with the treatment regimen and assess any adverse effects.

**Outcomes**

**Primary outcomes**

The patients improved lipid profiles, liver function tests, glycaemic control measures, and vitamin D levels at the end of the research.

**Secondary outcomes**

The decrease in the degree of steatosis in the US with the reduction in hs-CRP, NO, MDA, hepassocin, STAT-3, and TNF-α at the end of the study.

**Sample Size Calculation**

Based on data from prior research, the sample size was calculated using serum LDL-C as the primary dependent variable, a type I error of 0.05, and a study power of 85%. We concluded with the sample size of 50 patients in each group based on the recommended formula for parallel clinical trials, taking into consideration the dropout rate.

**Statistical Analysis**

The statistical analysis was carried out using GraphPad Prism version 7 (GraphPad Software, Inc., San Diego, CA, USA). To identify significant differences within groups before and after the intervention, the Paired Student’s t-test was used. An unpaired Student’s t-test was used to evaluate significant differences between groups before and after the intervention. The data was presented as the mean ± standard deviation (SD). For categorical data statistical analysis, the Chi-square test was used. All p-values were two-tailed, with (p < 0.05) considered statistically significant.

**Results**

**Clinical and Demographic Data in the Two Study Groups**

This study involved 100 NAFLD patients who were randomly assigned to groups 1 or 2. For four months, group one received standard treatment
A randomized placebo-controlled, double-blind study

plus a placebo; for four months, group two received standard conventional therapy plus cholecalciferol administered as a high oral loading dose of 300,000 IU followed by a daily oral dose of 800 IU. Table I displays their baseline statistics. There were no significant differences in demographic data between the studied groups; age (\( p = 0.206 \)), sex (\( p = 0.747 \)), weight (\( p = 0.790 \)), and height (\( p = 0.671 \)).

**Data for Anthropometric Measures in the Two Study Groups**

Regarding group 1, Table II shows that there were no significant variations in all measured parameters in comparison to after treatment as follows: weight (76.66 ± 9.447 vs. 76.36 ± 9.035, \( p = 0.365 \)), waist circumference (92.81 ± 16.99 vs. 93.77 ± 16.0, \( p = 0.589 \)), and body mass index (26.50 ± 2.715 vs. 26.43 ± 2.851, \( p = 0.547 \)) using paired \( t \)-test.

Regarding group 2, Table II shows that there were no significant variations in all measured parameters in comparison to after treatment as follows: weight (74.60 ± 9.311 vs. 74.50 ± 9.338, \( p = 0.540 \)), waist circumference (96.78 ± 14.98 vs. 97.29 ± 15.56, \( p = 0.587 \)), and body mass index (26.08 ± 3.562 vs. 18.24 ± 4.788, \( p = 0.759 \)) using paired \( t \)-test.

Table II showed that comparisons between groups using the unpaired \( t \)-test revealed no significant differences in baseline values between the studied groups. All measured parameters showed no significant change after four months of intervention.

**Glycaemic Index, Lipid Profile, Liver Function Tests, and Vitamin D Data in the Two Study Groups**

Regarding group 1, Table III shows that there were no significant variations in all measured parameters in comparison to after treatment as follows: fasting insulin (11.30 ± 2.309 vs. 11.64 ± 2.705, \( p = 0.094 \)), FBG (132.8 ± 15.99 vs. 132.5 ± 14.89, \( p = 0.871 \)), HOMA-IR (3.709 ± 0.922 vs. 3.802 ± 0.943, \( p = 0.330 \)), LDL (169.5 ± 20.87 vs. 170.9 ± 2.054, \( p = 0.069 \)), TG (171.8 ± 20.28 vs. 170.5 ± 18.67, \( p = 0.589 \)), HDL (45.14 ± 9.141 vs. 44.88 ± 9.147, \( p = 0.640 \)), ALT (53.52 ± 11.39 vs. 52.80 ± 10.84, \( p = 0.256 \)), AST (48.76 ± 11.90 vs. 49.06 ± 11.29, \( p = 0.80 \)), albumin (4.980 ± 0.850 vs. 4.8 ± 0.814, \( p = 0.219 \)), and vitamin D (18.5 ± 5.294 vs. 18.24 ± 4.788, \( p = 0.759 \)) using paired \( t \)-test.

Regarding group 2, Table III shows that there were no significant variations in the following measured parameters in comparison to after treatment as follows: fasting insulin (10.87 ± 3.303 vs.

---

**Table I.** Clinical and demographic data in the two study groups.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group (I)</th>
<th>Group (II)</th>
<th>( p )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>42.11 ± 13.97</td>
<td>46.06 ± 16.95</td>
<td>0.206</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>26/24</td>
<td>24/26</td>
<td>0.747</td>
</tr>
<tr>
<td>Height (m²)</td>
<td>1.702 ± 0.108</td>
<td>1.696 ± 0.098</td>
<td>0.671</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD; M: Male, F: Female; Significance at (\( p < 0.05 \)). Group 1: 50 patients received the standard conventional therapy in addition to a placebo for 4 months. Group 2: 50 patients were given the standard conventional therapy plus cholecalciferol as a high oral loading dose of 300,000 IU followed by a daily oral dose of 800 IU for 4 months.

**Table II.** Data for anthropometric measures in the two study groups.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group 1 Before treatment</th>
<th>Group 1 After treatment</th>
<th>( p )-value</th>
<th>Group 2 Before treatment</th>
<th>Group 2 After treatment</th>
<th>( p )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight (kg)</td>
<td>76.66 ± 9.447</td>
<td>76.36 ± 9.035</td>
<td>0.365</td>
<td>74.60 ± 9.311</td>
<td>74.50 ± 9.338</td>
<td>0.540</td>
</tr>
<tr>
<td>WC (cm)</td>
<td>92.81 ± 16.99</td>
<td>93.77 ± 16.0</td>
<td>0.589</td>
<td>96.78 ± 14.98</td>
<td>97.29 ± 15.56</td>
<td>0.587</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>26.50 ± 2.715</td>
<td>26.43 ± 2.851</td>
<td>0.547</td>
<td>26.08 ± 3.537</td>
<td>26.05 ± 3.562</td>
<td>0.606</td>
</tr>
</tbody>
</table>

Data are represented as mean ± SD; WC: Waist circumference, BMI: Body mass index, Kg: Kilogram, cm: Centimetre, \( p \)-value level within the same group by paired \( t \)-test. \( p \)-value level of significance between groups using unpaired \( t \)-test. Significance at (\( p < 0.05 \)). Group 1: 50 patients received the standard conventional therapy in addition to a placebo for 4 months. Group 2: 50 patients were given the standard conventional therapy plus cholecalciferol as a high oral loading dose of 300,000 IU followed by a daily oral dose of 800 IU for 4 months.
patients were vitamin D deficient and insufficient, respectively. At the end of the study, 42 patients in group 2 became vitamin D sufficient, 8 were found to be vitamin D insufficient, and no patient was found in the vitamin D deficient category. However, no significant difference was observed in the group 1 compared to their baseline categories.

**Analysis of Inflammatory And Oxidative Stress Biomarkers In The Two Study Groups**

Regarding group 1, Table IV shows that there were no significant differences in all measured parameters in comparison to after treatment as follows: TNF-α (368.3 ± 13.90 vs. 368.1 ± 19.08, p = 0.927), hs-CRP (10.41 ± 2.769 vs. 11.08 ± 2.290, p = 0.170), STAT-3 (94.68 ± 7.306 vs. 93.04 ± 6.709, p = 0.867), MD (65.73 ± 11.96 vs. 64.51 ± 13.04, p = 0.228), NO (281.4 ± 10.32 vs. 280.8 ± 9.562, p = 0.134), and heparosin (9.232 ± 0.5098 vs. 9.147 ± 0.4452, p = 0.275) using paired t-test.

Regarding group 2, Table IV shows that there were statistically significant differences in all measured parameters in comparison to after treatment apart from TNF-α as follows: TNF-α (367.6 ± 20.22 vs. 367.5 ± 20.09, p = 0.992), hs-CRP (9.475 ± 2.550 vs. 10.41 ± 2.769, p = 0.0008), STAT-3 (93.22 ± 9.04 vs. 94.68 ± 7.306, p = 0.0001), MD (65.73 ± 11.96 vs. 64.51 ± 13.04, p = 0.228), NO (281.4 ± 10.32 vs. 280.8 ± 9.562, p = 0.134), and heparosin (9.232 ± 0.5098 vs. 9.147 ± 0.4452, p = 0.275) using paired t-test.
A randomized placebo-controlled, double-blind study

Table IV demonstrates no significant difference in baseline values between groups when comparing them using an unpaired t-test. Apart from TNF-α, there were statistically significant changes in all studied markers after four months of intervention, as follows: TNF-α ($p = 0.890$), hs-CRP ($p = 0.0001$), STAT-3 ($p = 0.0001$), MD ($p = 0.0001$), NO ($p = 0.0001$), and hepassocin ($p = 0.0001$).

Regarding group 2, Figure 2 shows that there was no significant variation in the degree of steatosis as follows: mild degree (13 patients vs. 15), moderate degree (28 patients vs. 27), and severe degree (9 patients vs. 8).

None of the patients in group 2 reported any side effects after 4 months of daily cholecalciferol administration.

### Discussion

Globally, non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases affecting the population. In the absence of alcohol consumption, it is described as the build-up of fat in the hepatocytes that results in impaired liver function. Several tissues have
receptors for vitamin D, which is a fat-soluble vitamin. The genes controlling oxidative stress, inflammation, and the regulation of the liver’s lipid and glucose metabolism are all impacted by vitamin D receptors. A previous study on rats showed that decreased vitamin D intake is related to NAFLD development and progression through pathways involving oxidative stress and inflammation. A strong relationship between the stage and severity of NAFLD with low serum vitamin D levels was observed in several studies.

To our knowledge, this is the first randomized, placebo-controlled, double-blind study evaluating the effect of a high oral loading dose of vitamin D in NAFLD patients and its effect on serum hepassocin and STAT-3 followed by a daily maintenance dose of vitamin D for 4 months. The current study did not observe significant differences in serum TNF-α levels between the study groups. These findings were consistent with another research that evaluated the impact of vitamin D on TNF-α in NAFLD patients. In another study, oral supplementation with 40,000 IU vitamin D to overweight and obese subjects did not affect serum TNF-α levels after 1 year of supplementation. However, administering a single bolus dose (300,000 IU) of vitamin D2 in vitamin D-deficient subjects significantly increased serum TNF-α after 3 months. These contradictory findings could be attributed to various diseases, subjects, vitamin D supplementation types, and doses, follow-up time, and other unknown cellular mechanisms between vitamin D and inflammatory cytokines. More research in this field will shed light on more facts.

We observed that correcting vitamin D levels in NAFLD patients could lower serum MDA levels and enhance antioxidant capacity by down-regulating NO synthase activity, indicating yet another mechanism by which vitamin D may improve NAFLD. These findings are in line with other studies. MDA, a lipid peroxidation marker, is proven to increase in NAFLD patients and its effect on serum hepassocin and STAT-3 followed by a daily maintenance dose of vitamin D for 4 months. The current study revealed that vitamin D significantly reduced serum hepassocin compared to the baseline and control groups. This result came in accordance with other studies. Free fatty acids induce lipid building up in the liver and increase proinflammatory cytokines, including IL-6, which further activates STAT-3 to induce hepatic fibrosis. In addition to inflammation, hyperlipidemia induces the expression of hepassocin in primary hepatocytes. STAT-3 and hepatocyte nuclear factor-1 (HNF1) binding sites are found in the promoter region hepassocin, and IL-6 significantly induces the promoter activity of hepassocin, depending on the HNF1-binding site. Following the current research, vitamin D significantly reduced STAT-3 levels and de-
creased lipids accumulation, which may also indirectly decrease serum hepsasocin.

It is well known that NAFLD patients have significantly higher hs-CRP serum levels when compared to healthy subjects. Previous research found that hs-CRP is related to histopathologic changes in NAFLD that are independent of other risk factors. Suppressing serum hs-CRP levels would thus be an essential way to slow NAFLD progression and reduce the risk of cardiovascular disease, or at the very least, to comply with the therapy plan. We reported a significant decline in hs-CRP serum level, which was also reported by Foroughi et al, and Sharifi et al. In contrast, the vitamin D therapy regimen introduced by Barchetta et al and Sakpal et al did not significantly affect hs-CRP levels. According to previous research, 1,25(OH)2D suppresses T-helper1 cell activity in adipose tissue, reducing significantly decreased serum ALT after 4 months of administration, but no significant changes were seen in other liver enzyme biomarkers. This was also shown by Sakpal et al, who found that the serum level of ALT decreased after a single 600,000 IU vitamin D shot supplementation along with the standard management for 6 months. This finding was also supported by Amiri et al, who demonstrated that ALT significantly reduced after administering a small dose of about 25µg calcitriol (~1,000 IU) along with a high caloric diet for 3 months. In contrast, other studies reported no significant effects on ALT. Some cross-sectional studies reported a significant association between 25(OH)D serum levels and liver enzymes. After controlling for confounding variables, a recent population study found that having a high level of liver enzymes was linked with lower vitamin D levels. This result, however, was not statistically significant.

Furthermore, our study found that vitamin D positively impacts the lipid profile, with a significant decrease in serum TG, TC, and HDL levels. This finding agrees with Amiri et al and Sharifi et al. Results that confirmed the reducing effect of vitamin D on TG, TC, and LDL serum levels. Possible mechanisms for these effects include vitamin D’s involvement in increasing lipoprotein lipase activity in adipose tissue. Increased vitamin D levels may also be linked to lower serum parathyroid hormone levels;in-vitro experiments have shown that parathyroid hormone can reduce lipolysis. Furthermore, Carmeliet et al demonstrated that Vitamin D regulates calcium homeostasis by decreasing hepatic TG secretion, most likely by increasing calcium levels. Calcium also combines with bile acids, facilitating the combination’s fecal excretion. The greater the bile acid loss in feces, the greater the demand for new bile acids generated by the liver, and the lower serum cholesterol levels. As a result, vitamin D may lower cholesterol, triglyceride, and LDL levels by enhancing calcium absorption. Other investigations have found no significant link between vitamin D levels in NAFLD patients and abnormalities in the lipid profile.

Furthermore, concerning the glycaemic index and anthropometric parameters, our result did not reveal any beneficial effect of vitamin D on all these parameters at the end of the study. Likewise, previous trials did not report any significant changes in the anthropometric measures, but some studies showed controversial effects on the glycaemic index and insulin sensitivity. Some theories were proposed in the literature to understand the reason behind these conflicting results. Among the discussed reasons, it appears that the period of vitamin D supplementation and IR measuring techniques are the most prevalent in our study’s failure to document vitamin D effects on IR. To calculate IR, we used blood glucose and insulin levels. The euglycemic clamp technique or glucose tolerance testing may be more useful to properly measure insulin sensitivity.

Furthermore, based on von Hurst et al research findings, a longer treatment period may be required. South Asian women were given 4,000 IU/d of vitamin D3 for 6 months during this research. Despite the elevated 25(OH)D serum concentration after 3 months of therapy, they determined no meaningful improvement in insulin sensitivity until after 6 months. Conversely, two studies revealed a substantial decline in FBG and HOMA-IR.

Further, at the end of the study, no change in the degree of liver steatosis in the US was found in both group. Similarly, Barchetta et al did not report a significant difference in the fat fraction
measured by magnetic resonance after 24 weeks of oral high-dose vitamin D supplementation in T2DM patients with NAFLD. In contrast to our findings, El Amrousy et al. reported a significant improvement in hepatic steatosis and lobular inflammation by liver biopsy in the vitamin D group. A possible explanation for these differences may be attributed to different doses of vitamin D, study duration, and study populations.

**Limitations**

Although the study measures serum STAT-3 and hepassocin markers for the first time in NAFLD patients treated with Vitamin D, our study has two main limitations. Firstly, the lack of liver biopsy due to financial constraints hindered the follow-up of the histological changes in the liver. Secondly, the relatively short duration of the study. Further studies with a more extended period evaluating the histological changes in the liver with vitamin D loading and maintenance supplementation plans are required.

**Conclusions**

In conclusion, our randomized placebo-controlled trial demonstrated that hypovitaminosis D is common in NAFLD patients. High oral loading dose followed by daily oral doses of vitamin D had beneficial effects on serum ALT levels, hs-CRP levels, oxidative stress, STAT-3, hepassocin, and lipid profile of NAFLD patients.

**Ethics Approval**

The study protocol was revised and approved for scientific and ethical issues by the Institution Review Board of the Faculty of Medicine, Tanta University (approval code 35927/10/2022).

**Informed Consent**

Informed consent was obtained from all patients included in the study.

**Data Availability**

Due to privacy/ethical restrictions, data are available on request.

**Authors’ Contributions**

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis, and interpretation, or in all these areas; took part in drafting, revising, or critical-ly reviewing the article. All authors gave final approval of the version to be published and have agreed on the journal to which the article has been submitted; they agree to be accountable for all aspects of the work.

**Funding**

We greatly appreciate the support of Princess Nourah bint Abdulrahman University in funding this research through Princess Nourah bint Abdulrahman University Researchers Supporting Project Number (PNURSP2023R167), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.

**Acknowledgments**

The authors would like to thank all patients who contributed to the study and all the Staff of Tanta University Hospital for their help and support.

**Conflicts of Interest**

The authors declare no conflict of interest.

**References**

3) Moore JB. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis. Proc Nutr Soc 2019; 78: 290-304.


18) Barchetta I, Angelico F, Ben MD, Baroni MG, Pozzilli P, Morini S, Cavallo MG. Strong association between non-alcoholic fatty liver disease (NAFLD) and low 25 (OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med 2011; 14: 1249-1253.


56) Targher G. Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. J Hepatology 2006; 45: 879-881.


59) Barchetta I, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, Saulle R, Perri L, Morini S, Tiberti C. No effects of oral vitamin D sup-


77) von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient—a randomised, placebo-controlled trial. Br J Nutr 2010; 103: 549-555.